Season's Savings | ₹5/mo for 3 months

₹199/month after first 3 months. Renews automatically. Terms apply.
The Diabetes Control Loop: Lifestyle, Habits and Glucose Monitoring cover art

The Diabetes Control Loop: Lifestyle, Habits and Glucose Monitoring

The Diabetes Control Loop: Lifestyle, Habits and Glucose Monitoring

Written by: Doctor V.Dyachkov
Listen for free

About this listen
Type 2 diabetes isn't just about medication — it's about understanding how your daily habits create a loop that shapes your blood sugar. Each episode breaks down clinical research from PubMed.gov randomized controlled trials, revealing how diet, exercise, sleep, and stress influence glucose. Learn how continuous monitoring transforms treatment, how apps like Blood Sugar • Diabetes Control https://play.google.com/store/apps/details?id=com.flycode.sugarlevel Disclaimer: This podcast is for informational and educational purposes only and does not replace professional medical helpDoctor V.Dyachkov Hygiene & Healthy Living Physical Illness & Disease
Episodes
  • CGM Without Insulin: 82% of Non-Insulin Type 2 Diabetes Patients Improved Hyperglycemia (ADA 2026)
    Nov 12 2026

    CGM without insulin is changing type 2 diabetes care. A 2026 study presented at the American Diabetes Association's annual meeting found that 82% of adults with Type 2 diabetes not on insulin substantially reduced hyperglycemia using CGM. This episode explores how CGM without insulin works, why non-insulin type 2 diabetes monitoring matters, and what this means for the newly diagnosed and those managing with oral medications. We cover over-the-counter CGM options for non-insulin users, barriers to access, and how to overcome them. If you thought CGM was only for insulin users, this episode will change everything.

    Institutional AI Design • Agent-to-Agent Era

    Episode Highlights

    • The study population: adults with T2D not using insulin.
    • How CGM reduced hyperglycemia without insulin therapy.
    • Implications for the newly diagnosed and those managing with oral medications.
    • Over-the-counter CGM options for non-insulin users.
    • Barriers to access and how to overcome them.
    • Why CGM without insulin is becoming a core question in type 2 diabetes monitoring.

    Key Studies Referenced

    • 2026 ADA annual meeting study: 82% of non-insulin-treated adults with T2D substantially reduced hyperglycemia using CGM.
    • Analysis of CGM use in non-insulin type 2 diabetes and implications for oral medication management.
    • Real-world barriers to CGM access for non-insulin users and emerging over-the-counter options.

    Resources & Links

    Research Source – PubMed: CGM Without Insulin PubMed Search (https://pubmed.ncbi.nlm.nih.gov/?term=CGM+without+insulin+type+2+diabetes)

    AI Glucose Blood Monitoring App: Sugar Level | Diabetes Control (https://play.google.com/store/apps/details?id=com.flycode.sugarlevel)

    AI A2A HUB – Free Test Results Interpretation: AIDevMD (https://aidevmd.com/)

    Diabetes Support Group: https://t.me/sugarlvl (https://t.me/sugarlvl)

    Contact the Host: symptomd.com@gmail.com (symptomd.com@gmail.com)

    Transcript Teaser: “In this transcript, we unpack CGM without insulin: why 82% of non-insulin type 2 diabetes patients improved hyperglycemia, and what that means for monitoring, oral medications, and access.”

    SEO Keywords: CGM without insulin, non-insulin type 2 diabetes monitoring, hyperglycemia reduction, type 2 diabetes CGM, over-the-counter CGM, ADA 2026, continuous glucose monitor, diabetes technology, oral medication diabetes, CGM access, Sugar Level app, diabetes support.

    Medical Disclaimer: This podcast and description are for educational and informational purposes only and do not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions about a medical condition, medication, CGM use, diet, exercise, or diabetes management. Never disregard professional medical advice or delay seeking it because of something you heard or read here. Individual results may vary. The studies referenced do not imply that any app, product, or service can replace medical care. If you have type 1 diabetes, use insulin, are pregnant, or have other health conditions, consult your clinician before changing monitoring, food, activity, or medication.

    Show More Show Less
    32 mins
  • CGM vs Fingerstick: What the FreeDM2 Trial Really Means for Basal Insulin Users
    Nov 5 2026

    FreeDM2 trial: CGM vs fingerstick — a landmark 2026 randomized controlled trial across 24 UK centers just proved what many suspected: real-time CGM beats self-monitoring of blood glucose for people on basal insulin, and the gap only widens over time. In this episode, we break down the FreeDM2 trial design: 303 adults with type 2 diabetes on basal insulin plus SGLT2i or GLP-1 RA. HbA1c results at 16 weeks and 32 weeks show the CGM group dropping to 7.8% vs. 8.3% in the fingerstick arm. We explain why the benefit persisted during both self-management and clinician-supported phases, why severe hypoglycemia occurred twice in the SMBG control group and zero times in the CGM group, and what this means for insurance coverage, clinical practice, and real-time CGM type 2 diabetes care.

    Institutional AI Design • Agent-to-Agent Era

    Episode Highlights

    • FreeDM2 trial design: 303 adults, basal insulin plus SGLT2i or GLP-1 RA.
    • HbA1c results at 16 weeks and 32 weeks: CGM group drops to 7.8% vs. 8.3%.
    • Why the benefit persisted during both self-management and clinician-supported phases.
    • Severe hypoglycemia rates: two instances in the SMBG control group, none in CGM.
    • What this means for insurance coverage and clinical practice.
    • Why real-time CGM vs fingerstick is now a central question in type 2 diabetes care.

    Key Studies Referenced

    • FreeDM2 trial: 2026 randomized controlled trial across 24 UK centers.
    • 303 adults with type 2 diabetes on basal insulin plus SGLT2i or GLP-1 RA.
    • HbA1c at 16 and 32 weeks: real-time CGM vs self-monitoring of blood glucose.
    • Severe hypoglycemia: two events in the SMBG control group, zero in the CGM group.

    Resources & Links

    Research Source – PubMed: FreeDM2 Trial PubMed Search (https://pubmed.ncbi.nlm.nih.gov/?term=FreeDM2+trial+CGM+fingerstick)

    AI Glucose Blood Monitoring App: Sugar Level | Diabetes Control (https://play.google.com/store/apps/details?id=com.flycode.sugarlevel)

    AI A2A HUB – Free Test Results Interpretation: AIDevMD (https://aidevmd.com/)

    Diabetes Support Group: https://t.me/sugarlvl (https://t.me/sugarlvl)

    Contact the Host: symptomd.com@gmail.com (symptomd.com@gmail.com)

    Transcript Teaser: “In this transcript, we unpack the FreeDM2 trial: CGM vs fingerstick — and why real-time CGM type 2 diabetes management just got its strongest evidence yet.”

    SEO Keywords: FreeDM2 trial, CGM vs fingerstick, real-time CGM type 2 diabetes, basal insulin, SGLT2i, GLP-1 RA, HbA1c 7.8 vs 8.3, severe hypoglycemia, continuous glucose monitor, diabetes technology, CGM insurance coverage, type 2 diabetes clinical trial.

    Medical Disclaimer: This podcast and description are for educational and informational purposes only and do not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions about a medical condition, medication, CGM use, diet, exercise, or diabetes management. Never disregard professional medical advice or delay seeking it because of something you heard or read here. Individual results may vary. The studies referenced do not imply that any app, product, or service can replace medical care. If you have type 1 diabetes, use insulin, are pregnant, or have other health conditions, consult your clinician before changing monitoring, food, activity, or medication.

    Show More Show Less
    23 mins
  • The Digital Twin That Texts You: AI Diabetes Self-Management Beyond the Clinic
    Oct 29 2026

    Can a digital twin diabetes system text you personalized feedback between clinic visits? A 2026 npj Health Systems study tested a human-in-the-loop AI predictive digital twin that sends daily SMS feedback to adults with Type 2 diabetes. The results suggest this could scale precision diabetes care beyond the clinic. In this episode, we explain what a digital twin means in diabetes management, how the human-in-the-loop design combines AI predictions with clinician oversight, and what 6,467 longitudinal data points across weight, diet, activity, and glucose reveal. We also explore personalized SMS feedback as a scalable intervention and how AI diabetes self-management can extend precision diabetes support between visits.

    The Diabetes Control Loop: Lifestyle, Habits and Glucose Monitoring

    In this episode:

    • What a “digital twin” means in diabetes management.
    • The human-in-the-loop design: AI predictions plus clinician oversight.
    • 6,467 longitudinal data points across weight, diet, activity, and glucose.
    • Personalized SMS feedback as a scalable intervention.
    • Extending precision diabetes support beyond clinic visits.

    Sources and tools:

    PubMed search: Digital twin diabetes AI (https://pubmed.ncbi.nlm.nih.gov/?term=digital+twin+diabetes+AI)

    Sugar Level app: Sugar Level | Diabetes Control (https://play.google.com/store/apps/details?id=com.flycode.sugarlevel)

    AIDevMD: Free test results interpretation (https://aidevmd.com/)

    Support group: https://t.me/sugarlvl (https://t.me/sugarlvl)

    Contact: symptomd.com@gmail.com (symptomd.com@gmail.com)

    Transcript teaser: “In this transcript, we unpack digital twin diabetes: how an AI predictive digital twin texts personalized feedback between visits, and what it means for precision diabetes care and AI diabetes self-management.”

    Medical disclaimer: This episode is for education only and is not medical advice, diagnosis, or treatment. Always consult your physician or qualified health provider about your condition, medications, CGM use, diet, exercise, or diabetes management. Never stop or change medication without professional guidance. Individual results vary, and the studies discussed do not replace medical care.

    Show More Show Less
    43 mins
adbl_web_anon_alc_button_suppression_t1
No reviews yet